RYZ 811
Alternative Names: 68Ga-Ga-RYZ-GPC3; 68Ga-GPC3; 68Ga-GPC3 - Peptidream/RayzeBio; RYZ-811Latest Information Update: 22 Jun 2024
At a glance
- Originator PeptiDream; RayzeBio
- Developer RayzeBio
- Class Diagnostic agents; Imaging agents; Peptides; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Liver cancer
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from preclinical trial in Hepatocellular carcinoma presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Apr 2024 Clinical trials in Liver cancer (Diagnosis) in USA (unspecified route), prior to April 2024
- 05 Apr 2024 Pharmacodynamics data from first-in-human study in Hepatocellular carcinoma presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)